Eliem Therapeutics (ELYM) Competitors $3.01 -0.19 (-5.94%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ELYM vs. SELB, CUE, CGEN, ENOB, MEIP, KALV, ZVRA, GHRS, ORGO, and AQSTShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Selecta Biosciences (SELB), Cue Biopharma (CUE), Compugen (CGEN), Enochian Biosciences (ENOB), MEI Pharma (MEIP), KalVista Pharmaceuticals (KALV), Zevra Therapeutics (ZVRA), GH Research (GHRS), Organogenesis (ORGO), and Aquestive Therapeutics (AQST). These companies are all part of the "medical" sector. Eliem Therapeutics vs. Selecta Biosciences Cue Biopharma Compugen Enochian Biosciences MEI Pharma KalVista Pharmaceuticals Zevra Therapeutics GH Research Organogenesis Aquestive Therapeutics Selecta Biosciences (NASDAQ:SELB) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends. Is SELB or ELYM more profitable? Eliem Therapeutics has a net margin of 0.00% compared to Selecta Biosciences' net margin of -72.04%. Selecta Biosciences' return on equity of -44.13% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Selecta Biosciences-72.04% -44.13% -22.00% Eliem Therapeutics N/A -47.03%-45.97% Does the MarketBeat Community prefer SELB or ELYM? Selecta Biosciences received 322 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. However, 56.25% of users gave Eliem Therapeutics an outperform vote while only 55.44% of users gave Selecta Biosciences an outperform vote. CompanyUnderperformOutperformSelecta BiosciencesOutperform Votes33155.44% Underperform Votes26644.56% Eliem TherapeuticsOutperform Votes956.25% Underperform Votes743.75% Do institutionals & insiders have more ownership in SELB or ELYM? 42.0% of Selecta Biosciences shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 31.2% of Selecta Biosciences shares are held by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor SELB or ELYM? In the previous week, Selecta Biosciences' average media sentiment score of 0.00 equaled Eliem Therapeutics'average media sentiment score. Company Overall Sentiment Selecta Biosciences Neutral Eliem Therapeutics Neutral Which has more risk & volatility, SELB or ELYM? Selecta Biosciences has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500. Which has stronger valuation & earnings, SELB or ELYM? Selecta Biosciences has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Selecta Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSelecta Biosciences$110.78M0.00$35.38M-$0.22N/AEliem TherapeuticsN/AN/A-$35.12M-$0.53-5.68 SummarySelecta Biosciences beats Eliem Therapeutics on 9 of the 12 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.55M$6.38B$5.07B$8.66BDividend YieldN/A8.08%5.10%4.06%P/E Ratio-5.6810.51100.6017.27Price / SalesN/A244.531,195.1369.06Price / CashN/A53.4941.0336.35Price / Book0.779.306.345.87Net Income-$35.12M$154.14M$119.64M$225.66M7 Day Performance-20.58%-9.47%-5.13%-1.34%1 Month Performance-38.07%-7.30%-2.72%1.15%1 Year Performance18.50%28.21%31.10%24.02% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$3.01-5.9%N/A+22.9%$89.55MN/A-5.6820Gap DownSELBSelecta BiosciencesN/AN/AN/AN/A$136.76M$110.78M-4.0164Analyst ForecastGap DownHigh Trading VolumeCUECue Biopharma4.4657 of 5 stars$1.87+8.7%N/A-47.7%$90.96M$5.49M-1.9360Short Interest ↓News CoverageHigh Trading VolumeCGENCompugen2.7504 of 5 stars$1.74-2.2%N/A+126.1%$155.28M$33.46M-17.4068Earnings ReportShort Interest ↓ENOBEnochian BiosciencesN/AN/AN/AN/A$40.80MN/A0.0022News CoverageGap UpMEIPMEI Pharma4.247 of 5 stars$3.13+3.0%N/A-52.4%$20.85M$65.30M1.17100Earnings ReportAnalyst ForecastShort Interest ↑News CoverageKALVKalVista Pharmaceuticals3.8357 of 5 stars$11.09-2.8%N/A+24.7%$479.31MN/A-3.14150Positive NewsZVRAZevra Therapeutics3.5191 of 5 stars$8.96-0.4%N/A+101.4%$471.46M$23.69M-5.3365Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageGHRSGH Research1.9295 of 5 stars$9.04+5.0%N/A+24.2%$470.33MN/A-13.4910Short Interest ↑News CoverageORGOOrganogenesis4.1346 of 5 stars$3.50+6.7%N/A+52.6%$464.00M$433.14M-26.92950Earnings ReportAnalyst RevisionNews CoverageGap UpAQSTAquestive Therapeutics1.987 of 5 stars$5.07-7.1%N/A+158.1%$462.28M$50.58M-11.27160Short Interest ↓ Related Companies and Tools Related Companies Selecta Biosciences Alternatives Cue Biopharma Alternatives Compugen Alternatives Enochian Biosciences Alternatives MEI Pharma Alternatives KalVista Pharmaceuticals Alternatives Zevra Therapeutics Alternatives GH Research Alternatives Organogenesis Alternatives Aquestive Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELYM) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELYM Stock Alerts